MedPath

Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot

Not Applicable
Completed
Conditions
Diabetic Foot
Interventions
Device: Lipogems
Registration Number
NCT03276312
Lead Sponsor
University of Modena and Reggio Emilia
Brief Summary

This is a randomized controlled monocentric study on 114 diabetic patients with the aim of evaluating the efficacy of the lipofilling with Lipogems® system in diabetic patients that are candidates for a minor amputation in the foot. In particular, it will be evaluated whether the lipofilling will be able to shorten the healing times and to reduce the number of major amputations, with consequent positive impact on the quality of life. Patients will be randomized to the treatment group with Lipogems® (local injection of autologous micro-fractured adipose tissue) or to the control group, thus, treatment according to standard clinical practice.

Detailed Description

Primary objective of this study is the evaluation of the time of the healing of the lesions resulting from minor amputations (digital or forefoot) treated with Lipogems® technique.

Secondary objectives are: 1) assessment of the safety of the lipofilling; 2) evaluation of the intensity of pain (VAS); 3) assessment of the skin tropism; 4) calculation of the relapse rate (defined as the occurrence of local infections, dehiscence and suffering of skin flaps that lead to a revision of the amputation stump or amputation at a higher level); 5) evaluation of the time of hospitalization and quality of life (QoL).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
112
Inclusion Criteria
  1. Patients with diabetes (diabetes mellitus type 1 and type 2) of both sexes over the age of 18 years.
  2. Presence of irreversible gangrene digital or localized at forefoot (with X-ray of the foot negative or positive for osteolytic lesions at phalanges and/or metatarsus).
  3. Patients with vascular problems absent or resolved (evaluated with Eco Color Doppler and ABI (Ankle Brachial Index, that calculates the ratio of the systolic pressure measured at the ankle and the systolic pressure in the arm, both measured in supine position using wave continue Doppler. If assessable, it has to be greater than/equal to 0.7) and pressure index finger/arm TBI (Toe Brachial Index, if assessable, it has to be greater than/equal to 0.6) and/or by the determination of the transcutaneous oxygen pressure (TcPO2 that needs to be equal to or greater than 30mmHg).
Exclusion Criteria
  1. Oncological treatments ongoing or previous (past 5 years) and/or neoplastic lesions
  2. Patient under steroid therapy
  3. Active vascular issues

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionLipogemsLipogems - local injection of autologous micro-fragmented adipose tissue
Primary Outcome Measures
NameTimeMethod
Healing time6 months

Healing time after the minor amputation intended as the complete healing of the amputation stump

Secondary Outcome Measures
NameTimeMethod
Incidence of relapse6 months

Relapse is intended as revision of the amputation stump or amputation at a higher level

Pain assessed using the Visual Analogue Scale (VAS) for pain6 months

Pain will be assessed using the VAS pain scale

Total time of immobility6 months

Immobility of the patient will be assessed counting the number of bed rest days

Total time of hospitalization6 months

Hospitalization of the patient will be assessed counting the number of days in hospital

Quality of Life using the Short Form 36 (SF-36) questionnaire6 months

Assessment of the quality of life (QoL) before surgery and during all the subsequent follow up visits using the SF-36 questionnaire

Safety: All types of adverse events will be collected6 months

All types of adverse events will be collected

Trial Locations

Locations (1)

University of Modena and Reggio Emilia

🇮🇹

Modena, Italy

© Copyright 2025. All Rights Reserved by MedPath